Literature DB >> 17523312

The effects of a cyclooxygenase-2 inhibitor, FK3311, on total hepatic ischemia-reperfusion injury of the rat.

Mitsunobu Kobayashi1, Izumi Takeyoshi, Makoto Kurabayashi, Koshi Matsumoto, Yasuo Morishita.   

Abstract

BACKGROUND/AIMS: This study was designed to investigate the effects of a selective cyclooxygenase-2 inhibitor, FK3311, on warm ischemia-reperfusion injury of the rat liver.
METHODOLOGY: Male Sprague-Dawley rats were used in this experimental study. Total hepatic ischemia was induced with a clamping portal triad. The animals were divided into two groups: the control group and the FK group, in which FK3311 (FK, 1.0 mg/kg) was administered via the penile vein. The serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and lactate dehydrogenase (LDH) were measured 2 h after reperfusion, while those of thromboxane (Tx) B2 and 6-ketoprostaglandin (PG) F1alpha (stable metabolites of TxA2 and PGI2) were measured 30 min after reperfusion. The liver tissue blood flow was measured at preischemia, end-ischemia, and 30, 60, 90, and 120 min after reperfusion. The liver tissues obtained from animals at 2h after reperfusion were excised for histopathology.
RESULTS: The serum levels of AST, ALT, and LDH were significantly lower in the FK group than in the control group. Similarly, in the FK group, the serum levels of TxB2 were significantly lower than in the control group. By contrast, the 6-keto-PG F1a levels were not significantly reduced. The liver tissue blood flow at 120 min after reperfusion was significantly higher in the FK group than in the control group. The histopathological study showed that hepatic tissue damage was milder in the FK group than in the control group.
CONCLUSIONS: FK has protective effects on hepatic ischemia-reperfusion injury stemming from the marked inhibition of TxA2.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17523312

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  4 in total

1.  Monoacylglycerol lipase controls endocannabinoid and eicosanoid signaling and hepatic injury in mice.

Authors:  Zongxian Cao; Melinda M Mulvihill; Partha Mukhopadhyay; Huan Xu; Katalin Erdélyi; Enkui Hao; Eileen Holovac; György Haskó; Benjamin F Cravatt; Daniel K Nomura; Pál Pacher
Journal:  Gastroenterology       Date:  2013-01-04       Impact factor: 22.682

2.  Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3β signaling and mitochondrial permeability transition.

Authors:  Hailong Fu; Huan Chen; Chengcai Wang; Haitao Xu; Fang Liu; Meng Guo; Quanxing Wang; Xueyin Shi
Journal:  Mol Med       Date:  2012-09-25       Impact factor: 6.354

3.  Cyclooxygenase-2 deficiency enhances Th2 immune responses and impairs neutrophil recruitment in hepatic ischemia/reperfusion injury.

Authors:  Takashi Hamada; Seiichiro Tsuchihashi; Armine Avanesyan; Sergio Duarte; Carolina Moore; Ronald W Busuttil; Ana J Coito
Journal:  J Immunol       Date:  2008-02-01       Impact factor: 5.422

4.  Hepatic ischemia and reperfusion injury in the absence of myeloid cell-derived COX-2 in mice.

Authors:  Sergio Duarte; Hiroyuki Kato; Naohisa Kuriyama; Kathryn Suko; Tomo-O Ishikawa; Ronald W Busuttil; Harvey R Herschman; Ana J Coito
Journal:  PLoS One       Date:  2014-05-12       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.